Reports

Sale

Exanthema Market Size, Share, Trends, Research, Forecast: By Disease Type: Bacterial, Viral, Others; By Therapy Type: Chemotherapy, Radiation Therapy, Targeted Therapy; By Treatment: Anti-Pyretic, Emollients, Liquids, Others; By Drugs; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Exanthema Market Outlook

The exanthema market size was valued at USD 1390.27 million in 2023, driven by the increasing incidence of viral and bacterial infections and innovations in diagnostic methods across the 8 major markets. The market size is anticipated to grow at a CAGR of 6.10% during the forecast period of 2024-2032 to achieve a value of USD 2231.8 million by 2032.

Exanthema Market Overview

Exanthema is commonly triggered by infections, often viral, and can manifest as a response to toxins from the organism, skin damage, or an immune reaction. These rashes, nonspecific in nature, show as spots or blotches that may or may not cause itching. They typically spread widely across the body, often more prominently on the trunk than the limbs. Before the rash appears, patients might experience a range of general symptoms including fever, malaise, headaches, reduced appetite, abdominal pain, irritability, muscle aches, and pains.

The exanthema market growth is driven by the rising incidence of viral and bacterial infections, causing skin rashes and related diseases. The escalating prevalence of infectious diseases like measles, rubella, and chickenpox, is significantly contributing to increased exanthema cases, which is expected to require enhanced attention to provide preventive measures and vaccinations, further propelling the market growth. The market is further driven by improvements in healthcare facilities and infrastructure to provide better diagnosis, treatment, and management of exanthemas, encouraging more people to seek medical care.

Consequently, the market is also witnessing innovations in diagnostic methods such as molecular testing and serological assays, acting as major drivers to further bolster the exanthema market demand. Governments and healthcare organizations are launching interesting initiatives to promote vaccination campaigns, especially for diseases linked to exanthemas are contributing to increased market demand.

Initiatives Aiding the Market Growth

The market demand is anticipated to experience significant growth due to a combination of factors such as national and international organizations acting and launching initiatives toward the prevention of exanthema in regions. For instance, the IA2030 Measles & Rubella Partnership, a collaborative initiative led by multiple prominent entities in the field of healthcare and immunization including the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccine Alliance, the Bill and Melinda Gates Foundation, UNICEF, and the World Health Organization (WHO). Such initiatives are aligned towards a common goal of spreading awareness regarding exanthema, likely to contribute significantly to the rising exanthema market share.

Surge in Supplies Due to Unforeseen Outbreak

The market is witnessing a surge in demand for increased treatment supplies and drugs due to the emergence of the condition in some regions. For instance, a recent surge in measles cases in Romania including 460 confirmed cases by August 2023 and significant outbreaks in several counties, has escalated the urgency for effective interventions and preventive measures, elevating the demand for relevant treatments and vaccinations. The market growth is expected to witness escalation owing to the sudden surge in the demand for treatment and vaccination in affecting regions.

FDA Approvals to Aid the Market Growth

The exanthema market growth is also driven by new FDA approvals creating a wave of hope for healthcare professionals and patients. For instance, Merck's groundbreaking announcement of the FDA's approval for intramuscular administration of the MMRV family vaccines—M-M-R®II, VARIVAX®, and ProQuad® marks have also collectively marked a pivotal advancement. This alteration from the conventional subcutaneous injection to intramuscular administration broadens the vaccination landscape enhancing convenience and accessibility as well. Such developments signify promising increased demand for the exanthem market in the forecast period.

Exanthema Market Segmentations

Market Breakup by Disease Type

Bacterial

Viral

Others

Market Breakup by Therapy Type

Chemotherapy

Radiation Therapy

Targeted Therapy

Market Breakup by Treatment

Anti-Pyretic

Emollients

Liquids

Others

Market Breakup by Drugs

Corticosteroids

Antiseizure Agents

Others

Market Breakup by Route of Administration

Oral

Parenteral

Others

Market Breakup by Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Market Breakup by Region

United States

EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom

Japan

China

Exanthema Market Regional Analysis

Considering the geographical landscape, the United States is leading the regional market. The market is expected to dominate in the forecast period due to factors such as the presence of the largest patient pool for exanthema and also representing the largest market for its treatment.

The latest data by the CDC Centers for Disease Control and Prevention has revealed that more than 3,700 babies were born with syphilis in 2022, which was more than 10 times the number in 2012. The increase in newborn syphilis follows rising syphilis cases among women of reproductive age combined with social and economic factors that create barriers to high-quality prenatal care and ongoing declines in the prevention infrastructure and resources.

The United States has seen a rise in cases of syphilis and congenital syphilis, leading senior leadership at the U.S. Department of Health and Human Services (HHS) to establish the National Syphilis and Congenital Syphilis Syndemic Federal Taskforce. This task force is dedicated to leading a national public health response to address the issue.

Exanthema Market: Competitor Landscape

In February 2023, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicella-zoster virus (VZV). Shingles affects millions of people around the world each year.

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Pfizer Inc

F. Hoffmann-La Roche Ltd

Mylan N.V.

Fresenius Kabi AG

Hikma Pharmaceuticals PLC

Teva Pharmaceutical Industries

Bristol Myers Squibb Company

Bayer AG

Sun Pharmaceutical Industries

Manus Aktteva Biopharma LLP

Perrigo Company plc

Novartis AG

GSK Plc.

CIRON Drugs & Pharmaceuticals Pvt. Ltd.

Concord Laboratories

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES	DETAILS
Base Year	2023
Historical Period	2017-2023
Forecast Period	2024-2032
Scope of the Report	Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment: Disease Type Therapy Type Treatment Drugs Route of Administration Distribution Channel Region
Breakup by Disease Type	Bacterial Viral Others
Breakup by Therapy Type	Chemotherapy Radiation Therapy Targeted Therapy
Breakup by Treatment	Anti-Pyretic Emollients Liquids Others
Breakup by Drugs	Corticosteroids Antiseizure Agents Others
Breakup by Route of Administration	Oral Parenteral Others
Breakup by Distribution Channel	Hospital Pharmacy Retail Pharmacy
Breakup by Region	United States EU-4 and the United Kingdom Japan China
Market Dynamics	Market Drivers and Constraints SWOT Analysis Porter’s Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis
Competitive Landscape	Market Structure Company Profiles Financial Analysis Product Portfolio Demographic Reach and Achievements Mergers and Acquisitions Certifications
Companies Covered	Pfizer Inc F. Hoffmann-La Roche Ltd Mylan N.V. Fresenius Kabi AG Hikma Pharmaceuticals PLC Teva Pharmaceutical Industries Bristol Myers Squibb Company Bayer AG Sun Pharmaceutical Industries Manus Aktteva Biopharma LLP Perrigo Company plc Novartis AG GSK Plc. CIRON Drugs & Pharmaceuticals Pvt. Ltd. Concord Laboratories

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1   Preface
   1.1   Objectives of the Study
   1.2   Key Assumptions
   1.3   Report Coverage – Key Segmentation and Scope
   1.4   Research Methodology
2   Executive Summary
3   Exanthema Overview
   3.1   Guidelines and Stages
   3.2   Pathophysiology
   3.3   Screening and Diagnosis
   3.4   Treatment Pathway
4   Patient Profile
   4.1   Patient Profile Overview
   4.2   Patient Psychology and Emotional Impact Factors
   4.3   Risk Assessment and Treatment Success Rate
5   Exanthema Epidemiology Analysis – 8 Major Markets
   5.1   8MM Epidemiology Scenario Overview (2017-2032)
   5.2   United States Exanthema Epidemiology Forecast (2017-2032)
   5.3   EU-4 and United Kingdom Exanthema Epidemiology Forecast (2017-2032)
       5.3.1   Germany Exanthema Epidemiology Forecast (2017-2032)
       5.3.2   France Exanthema Epidemiology Forecast (2017-2032)
       5.3.3   Italy Exanthema Epidemiology Forecast (2017-2032)
       5.3.4   Spain Exanthema Epidemiology Forecast (2017-2032)
       5.3.5   United Kingdom Exanthema Epidemiology Forecast (2017-2032)
   5.4   Japan Exanthema Epidemiology Forecast (2017-2032)
   5.5   China Exanthema Epidemiology Forecast (2017-2032)
6   Exanthema Market Overview – 8 Major Markets
   6.1   Exanthema Market Historical Value (2017-2023)
   6.2   Exanthema Market Forecast Value (2024-2032)
7   Exanthema Market Landscape – 8 Major Markets
   7.1   Exanthema Developers Landscape
       7.1.1   Analysis by Year of Establishment
       7.1.2   Analysis by Company Size
       7.1.3   Analysis by Region
   7.2   Exanthema Product Landscape
       7.2.1   Analysis by Disease Type
       7.2.2   Analysis by Therapy Type
       7.2.3   Analysis by Treatment
       7.2.4   Analysis by Drugs
       7.2.5   Analysis by Route of Administration
       7.2.6   Analysis by Distribution Channel
8   Exanthema Challenges and Unmet Needs
   8.1   Treatment Pathway Challenges
   8.2   Compliance and Drop-Out Analysis
   8.3   Awareness and Prevention Gaps
9   Cost of Treatment
10   Exanthema Market Dynamics
   10.1   Market Drivers and Constraints
   10.2   SWOT Analysis
       10.2.1   Strengths
       10.2.2   Weaknesses
       10.2.3   Opportunities
       10.2.4   Threats
   10.3   Porter’s Five Forces Model
       10.3.1   Bargaining Power of Suppliers
       10.3.2   Bargaining Power of Buyers
       10.3.3   Threat of New Entrants
       10.3.4   Threat of Substitutes
       10.3.5   Degree of Rivalry
   10.4   Key Demand Indicators
   10.5   Key Price Indicators
   10.6   Industry Events, Initiatives, and Trends
   10.7   Value Chain Analysis
11   Exanthema Market Segmentation – 8 Major Markets
   11.1   Exanthema Market by Disease Type
       11.1.1   Market Overview
       11.1.2   Bacterial
       11.1.3   Viral
       11.1.4   Others
   11.2   Exanthema Market by Therapy Type
       11.2.1   Market Overview
       11.2.2   Chemotherapy
       11.2.3   Radiation Therapy
       11.2.4   Targeted Therapy
   11.3   Exanthema Market by Treatment
       11.3.1   Market Overview
       11.3.2   Anti-Pyretic
       11.3.3   Emollients
       11.3.4   Liquids
       11.3.5   Others
   11.4   Exanthema Market by Drugs
       11.4.1   Market Overview
       11.4.2   Corticosteroids
       11.4.3   Antiseizure Agents
       11.4.4   Others
   11.5   Exanthema Market by Route of Administration
       11.5.1   Market Overview
       11.5.2   Oral
       11.5.3   Parenteral
       11.5.4   Others
   11.6   Exanthema Market by Distribution Channel
       11.6.1   Market Overview
       11.6.2   Hospital Pharmacy
       11.6.3   Retail Pharmacy
   11.7   Exanthema Market by Region
       11.7.1   Market Overview
       11.7.2   United States
       11.7.3   EU-4 and the United Kingdom
           11.7.3.1   Germany
           11.7.3.2   France
           11.7.3.3   Italy
           11.7.3.4   Spain
           11.7.3.5   United Kingdom
       11.7.4   Japan
       11.7.5   China
12   United States Exanthema Market
   12.1   United States Exanthema Market Historical Value (2017-2023)
   12.2   United States Exanthema Market Forecast Value (2024-2032)
   12.3   United States Exanthema Market by Disease Type
       12.3.1   Market Overview
       12.3.2   Bacterial
       12.3.3   Viral
       12.3.4   Others
   12.4   United States Exanthema Market by Therapy Type
       12.4.1   Market Overview
       12.4.2   Chemotherapy
       12.4.3   Radiation Therapy
       12.4.4   Targeted Therapy
13   EU-4 and United Kingdom Exanthema Market
   13.1   EU-4 and United Kingdom Exanthema Market Historical Value (2017-2023)
   13.2   EU-4 and United Kingdom Exanthema Market Forecast Value (2024-2032)
   13.3   EU-4 and United Kingdom Exanthema Market by Disease Type
       13.3.1   Market Overview
       13.3.2   Bacterial
       13.3.3   Viral
       13.3.4   Others
   13.4   EU-4 and United Kingdom Exanthema Market by Therapy Type
       13.4.1   Market Overview
       13.4.2   Chemotherapy
       13.4.3   Radiation Therapy
       13.4.4   Targeted Therapy
14   Japan Exanthema Market
   14.1   Japan Exanthema Market Historical Value (2017-2023)
   14.2   Japan Exanthema Market Forecast Value (2024-2032)
   14.3   EU-4 and United Kingdom Exanthema Market by Disease Type
       14.3.1   Market Overview
       14.3.2   Bacterial
       14.3.3   Viral
       14.3.4   Others
   14.4   EU-4 and United Kingdom Exanthema Market by Therapy Type
       14.4.1   Market Overview
       14.4.2   Chemotherapy
       14.4.3   Radiation Therapy
       14.4.4   Targeted Therapy
15   Patent Analysis
   15.1   Analysis by Type of Patent
   15.2   Analysis by Publication year
   15.3   Analysis by Issuing Authority
   15.4   Analysis by Patent Age
   15.5   Analysis by CPC Analysis
   15.6   Analysis by Patent Valuation
   15.7   Analysis by Key Players
16   Grants Analysis
   16.1   Analysis by year
   16.2   Analysis by Amount Awarded
   16.3   Analysis by Issuing Authority
   16.4   Analysis by Grant Application
   16.5   Analysis by Funding Institute
   16.6   Analysis by NIH Departments
   16.7   Analysis by Recipient Organization
17   Clinical Trials Analysis
   17.1   Analysis by Trial Registration Year
   17.2   Analysis by Trial Status
   17.3   Analysis by Trial Phase
   17.4   Analysis by Therapeutic Area
   17.5   Analysis by Geography
18   Funding Analysis
   18.1   Analysis by Funding Instances
   18.2   Analysis by Type of Funding
   18.3   Analysis by Funding Amount
   18.4   Analysis by Leading Players
   18.5   Analysis by Leading Investors
   18.6   Analysis by Geography
19   Partnership and Collaborations Analysis
   19.1   Analysis by Partnership Instances
   19.2   Analysis by Type of Partnership
   19.3   Analysis by Leading Players
   19.4   Analysis by Geography
20   Supplier Landscape
   20.1   Pfizer Inc
       20.1.1   Financial Analysis
       20.1.2   Product Portfolio
       20.1.3   Demographic Reach and Achievements
       20.1.4   Mergers and Acquisition
       20.1.5   Certifications
   20.2   F. Hoffmann-La Roche Ltd
       20.2.1   Financial Analysis
       20.2.2   Product Portfolio
       20.2.3   Demographic Reach and Achievements
       20.2.4   Mergers and Acquisition
       20.2.5   Certifications
   20.3   Mylan N.V.
       20.3.1   Financial Analysis
       20.3.2   Product Portfolio
       20.3.3   Demographic Reach and Achievements
       20.3.4   Mergers and Acquisition
       20.3.5   Certifications
   20.4   Fresenius Kabi AG
       20.4.1   Financial Analysis
       20.4.2   Product Portfolio
       20.4.3   Demographic Reach and Achievements
       20.4.4   Mergers and Acquisition
       20.4.5   Certifications
   20.5   Hikma Pharmaceuticals PLC
       20.5.1   Financial Analysis
       20.5.2   Product Portfolio
       20.5.3   Demographic Reach and Achievements
       20.5.4   Mergers and Acquisition
       20.5.5   Certifications
   20.6   Teva Pharmaceutical Industries
       20.6.1   Financial Analysis
       20.6.2   Product Portfolio
       20.6.3   Demographic Reach and Achievements
       20.6.4   Mergers and Acquisition
       20.6.5   Certifications
   20.7   Bristol Myers Squibb Company
       20.7.1   Financial Analysis
       20.7.2   Product Portfolio
       20.7.3   Demographic Reach and Achievements
       20.7.4   Mergers and Acquisition
       20.7.5   Certifications
   20.8   Bayer AG
       20.8.1   Financial Analysis
       20.8.2   Product Portfolio
       20.8.3   Demographic Reach and Achievements
       20.8.4   Mergers and Acquisition
       20.8.5   Certifications
   20.9   Sun Pharmaceutical Industries
       20.9.1   Financial Analysis
       20.9.2   Product Portfolio
       20.9.3   Demographic Reach and Achievements
       20.9.4   Mergers and Acquisition
       20.9.5   Certifications
   20.10   Manus Aktteva Biopharma LLP
       20.10.1   Financial Analysis
       20.10.2   Product Portfolio
       20.10.3   Demographic Reach and Achievements
       20.10.4   Mergers and Acquisition
       20.10.5   Certifications
   20.11   Perrigo Company plc
       20.11.1   Financial Analysis
       20.11.2   Product Portfolio
       20.11.3   Demographic Reach and Achievements
       20.11.4   Mergers and Acquisition
       20.11.5   Certifications
   20.12   Novartis AG
       20.12.1   Financial Analysis
       20.12.2   Product Portfolio
       20.12.3   Demographic Reach and Achievements
       20.12.4   Mergers and Acquisition
       20.12.5   Certifications
   20.13   GSK Plc.
       20.13.1   Financial Analysis
       20.13.2   Product Portfolio
       20.13.3   Demographic Reach and Achievements
       20.13.4   Mergers and Acquisition
       20.13.5   Certifications
   20.14   CIRON Drugs & Pharmaceuticals Pvt. Ltd.
       20.14.1   Financial Analysis
       20.14.2   Product Portfolio
       20.14.3   Demographic Reach and Achievements
       20.14.4   Mergers and Acquisition
       20.14.5   Certifications
   20.15   Concord Laboratories
       20.15.1   Financial Analysis
       20.15.2   Product Portfolio
       20.15.3   Demographic Reach and Achievements
       20.15.4   Mergers and Acquisition
       20.15.5   Certifications
21   Exanthema Market - Distribution Model (Additional Insight)
   21.1   Overview
   21.2   Potential Distributors
   21.3   Key Parameters for Distribution Partner Assessment
22   Key Opinion Leaders (KOL) Insights (Additional Insight)
23   Company Competitiveness Analysis (Additional Insight)
   23.1   Very Small Companies
   23.2   Small Companies
   23.3   Mid-Sized Companies
   23.4   Large Companies
   23.5   Very Large Companies
24   Payment Methods (Additional Insight)
   24.1   Government Funded
   24.2   Private Insurance
   24.3   Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

What was the exanthema market value in 2023?

The market attained a value of about USD 1390.27 million in 2023 driven by increasing bacterial infections.

What is the exanthema market forecast outlook for 2024-2032?

The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2024-2032 and is likely to reach a market value of USD 2231.8 million by 2032.

What major factors aid the exanthema market demand?

The market demand is propelled by the launch of effective and collaborative initiatives led by multiple prominent entities in the field of healthcare and immunization, the increasing cases of syphilis, the surge in supplies due to the measles outbreak in Romania, the increasing number of clinical trials by the market players to bring the best and effective treatment for exanthema in the market.

What are the major exanthema market trends?

The new FDA approvals such as the FDA's approval for intramuscular administration of the MMRV family vaccines M-M-R®II, VARIVAX®, and ProQuad® marks, marking pivotal advancements are a major trend influencing the market growth.

What are the 8 major regional markets for exanthema, according to the EMR report?

The 8 major regions of the market include the United States, EU-4, the United Kingdom, Japan, and China.

What disease types can trigger exanthema in people?

Bacterial and viral diseases among others may trigger exanthema in people.

What type of therapies can treat exanthema?

Exanthema can be treated by chemotherapy, radiation therapy, and targeted therapy.

What other types of treatments can cure the condition?

This medical condition can be cured by anti-pyretic, emollients, and liquids, among others.

What type of drugs can be used to treat exanthema in the market?

Corticosteroids and antiseizure agents among others can be used to treat exanthema in the market.

What are the routes of administration for the appropriate treatments?

Routes of administration include oral, and parenteral, among others.

What are the distribution channels in the market?

Distribution channels include hospital pharmacies and retail pharmacies.

Who are the key players involved in the exanthema market?

Key players involved in the market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries, Bristol Myers Squibb Company, Bayer AG, Sun Pharmaceutical Industries, Manus Aktteva Biopharma LLP, Perrigo Company plc, Novartis AG, GSK Plc., CIRON Drugs & Pharmaceuticals Pvt. Ltd., and Concord Laboratories.

Request Sample

Purchase Full Report

Mini Report

$ ~~3299~~ $2999

Selected Sections, One User
Printing Not Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Single User License

$ ~~6599~~ $5999

All Sections, One User
One Print Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Five User License

$ ~~8799~~ $7999

All Sections, Five Users
Five Prints Allowed
Email Delivery in PDF
Free Limited Customisation
Post Sales Analyst Support
~~50% Discount on Next Update~~

Buy Now

Corporate License

$ ~~9899~~ $8999

All Sections, Unlimited Users
Unlimited Prints Allowed
Email Delivery in PDF + Excel
Free Limited Customisation
Post Sales Analyst Support
50% Discount on Next Update

Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER